Please use this identifier to cite or link to this item:
Type: Outro documento
Title: Phase 2 clinical trial of the gi safety of a hydrogen sulfide-releasing anti-inflammatory drug (atb-346)
Author: Wallace, John
Buret, Andre
Nagy, Peter
Muscara, Marcelo
de Nucci, Gilberto
Abstract: Hydrogen sulfide (H2S) is a naturally occurring gaseous mediator produced by intestinal bacteria and various eukaryotic cells. H2S exerts anti-inflammatory, pro-resolution and cytoprotective effects in vivo. ATB-346 is an H2S-releasing derivative of naproxen, which in animals was shown to produce negligible gastrointestinal (GI) damage and bleeding. In human studies, ATB-346 was found to be much more potent and long-lasting than naproxen. A phase 2 open-label efficacy study demonstrated that ATB-346 (250 mg daily) significantly reduced pain in patients with osteoarthritis of the knee, and markedly suppressed cyclooxygenase (COX) activity. The aim of the present study was to determine if ATB-346 would induce less gastroduodenal ulceration than standard dose naproxen
Subject: Anti-inflamatórios
Country: Reino Unido
Editor: BMJ
Rights: Fechado
Identifier DOI: 10.1136/annrheumdis-2019-eular.568
Date Issue: 2019
Appears in Collections:FCM - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
000472207101371.pdf135.74 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.